KQ Labs’ Post

That’s a wrap! Another exciting PharmStars Alumni Showcase for the books took place last week. PharmStars’ unique #DigitalHealth #accelerator doesn’t end for our startups after graduation from PharmaU. This event was yet another opportunity to engage our #pharma members, investors, press and fellow startup leaders. We thank all the attendees for joining us and for contributing - we’ve already heard about many follow-up conversations planned with our startups. Thanks to our pharma members who bring the hard questions and provide such encouraging support: Alexion Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Pfizer, and Sumitomo Pharma America, Inc. Thanks also to representatives from these investor groups. Their interest and input help fuel the startups’ activities and priorities: Fusion Fund, Hikma Ventures, Innospark Ventures, and Touchdown Ventures. And thanks to the members of the press who joined us to help spread the word about these rapidly advancing companies. What achievements and accomplishments did these #PharmStarsAlumni from our Fall 2022 Cohort “Digital #Innovations in Real World Evidence” report at our Showcase? ⭐Raising millions in capital in a tough funding environment ⭐Receipt of many awards, prizes, and recognition ⭐Strengthening, expanding and/or pivoting their digital health products ⭐Publication of scientific papers and case studies  ⭐Partnerships with providers and big tech firms ⭐⭐ Pharma deals galore! 9 with PharmStars members and 50 with other biopharma partners Stay tuned for another post with details on these PharmStars alumni startup milestones that were shared at the Showcase. If you want to become a PharmStars alumni or member, and participate in a future Showcase, check out www.Pharmstars.com for more information. Meredith Cohen Marcella Rogers Joanne Kamens, PhD #accelerator #innovation #DigitalHealth #startup #pharma #DigitalInnovation #healthcare #medtech #HealthIt #biopharma #oncology #entrepreneurship

This year, biotech and healthcare startups have taken the lead in U.S. Series A funding, securing $5.6 billion across 110 rounds. This represents 53% of all Series A investments. The largest Series A rounds have gone to companies like Xaira Therapeutics and Mirador Therapeutics. This trend highlights a shift in the startup ecosystem, with significant capital flowing into health and biotech sectors. https://lnkd.in/d-B5UKr8

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/drE4thXY Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dMu5TpiV Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Share prices of the two biotech startups that made their public debuts last week have been soaring. Pitchbook believes that the current wave of biotech startups could open up the IPO window for tech startups, as both sectors have shown a strong correlation in the past. However, EY's U.S. VC leader, Jeff Grabow, dismissed Pitchbook's forecasts as he believes that biotechs do not consider an IPO as a liquidity event and often launch their IPO offerings even when the market conditions are unfavorable. Typically, tech startups rely on IPO as a liquidity event and have to factor in the broader market conditions to have a successful debut. But for biotech companies, an IPO is often the best place to raise large sums of money to fund their drug trials in later stages. Although closely correlated, the success of tech IPOs will depend upon other public debuts, especially the bigger tech brands that are able to test the market conditions. Bladder cancer drug developer CG Oncology raised $380M at its IPO listing last week, while Arrivent Biopharma raised $175M a couple of days later. Other biotech companies lining up their IPO listings include Alto Neuroscience and Fractyl Health.

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Wow, what a journey! 🚀 We are proud to announce today that our start-up directory on bionity.com has reached the magic number of 1,000! A milestone that stands not only for quantity, but above all for quality and innovation in the field of 🧬 life sciences, biotechnology and pharma. But how did we come to place such a focus on the vibrant world of start-ups? It all started with a vision of our founder and CEO Stefan, who recognized the potential of young, dynamic companies in 2018 and decided to offer them a stage on our industry platforms. 🥇 Our goal was clear: more visibility for the innovative ideas of start-ups and at the same time a fresh, dynamic wind for our platform. We wanted to meet the company founders where their journey begins and create a community that thrives on mutual dynamics. The journey with these 1,000 start-ups was a revelation. Not only did we learn that start-ups are sometimes too reticent to tell their stories (yes, we're looking at you, you "interview-shy" innovators 😉), but also that the world of life sciences and pharma is an inexhaustible source of inspiration. And apparently also more innovative than the chemical industry, for example, where there are significantly fewer start-ups. 🤔 Our newest members in the directory include HyPhoX, TRYPTO Therapeutics, IntegraSkin, VALANX Biotech, Mallia Therapeutics, DISCO Pharmaceuticals GmbH and RIANA Therapeutics. A big thank you to all these pioneers who are pushing the boundaries of what is possible together with us. We invite you to become part of our community, shape the future and discover the stories behind these innovative companies. Take a look and be inspired: https://lnkd.in/dpy5Awap Together, we are shedding light on the world of life sciences and creating space for the next generation of visionaries. Here's to the next 1,000! 🌟 #LifeScience #Biotech #Startups #LUMITOS #bionity #ShapingTheFuture LUMITOS AG

Biotech funding is on the rise again, and here's why... Curie.Bio is leading the charge! 👇 Bio secures $380m, nearly $1bn total raised since launch👇 🌱THE BASICS → Curie.Bio raised $380m, targeting early-stage biotech startups. → The accelerator launched in February 2023 with $520m from GV, ARCH Venture Partners, and Leaps by Bayer. → Focuses on Series A investments, advancing companies towards clinical proof-of-concept studies. 🤓 THE ADVANCED → Provides seed-stage funding and essential services to startups. → Addresses the biotech funding gap where initial investments are scarce compared to the tech industry. → Launched by Alexis Borisy, Zach Weinberg, and Christoph Lengauer to support founder-led biotech's with extensive guidance. 😲 THE SURPRISING → Despite a significant downturn in private biotech venture financing in 2022 and 2023, Curie.Bio thrived. → Curie.Bio now supports 20 early-stage therapeutics companies. → Forward Therapeutics, Curie.Bio’s first portfolio company, raised $50m and progressed to clinic readiness in 18 months. 👇 ACT NOW! 👇 Biotech innovators, this is your moment. Leverage Exigyn's Budgeting & Planning module to transform your groundbreaking ideas into clinical realities. The biotech funding landscape is shifting—start preparing now to ride the wave of recovery. And don’t forget to like this post ❤️ if you found it useful. #Biotech #BiotechFunding #CurieBio #VentureCapital #StartupFunding #SeriesA #ClinicalTrials #Innovation #Healthcare #BiotechStartups #EarlyStageFunding #Investment #GV #ARCHVenturePartners #LeapsByBayer #Therapeutics #SeedFunding #FounderSupport #Biopharma #DrugDevelopment #ForwardTherapeutics #InvestmentPool #BiotechAccelerator #HealthcareInnovation #FundingGap #StartupEcosystem #BiotechInvestors #2023 #2024 #Recovery #IndustryTrends #Startups

🙋♀️ Do you believe in the promise of #DigitalHealth to improve #patient outcomes and #reducecost in #drugdevelopment and #caredelivery? 💊 📲 Do you want to know how to bridge the gap between #pharma and digital #health #startups working on these innovative solutions? 💥 PharmStars knows how to bring startups and #biopharma together to bridge that gap! Our 10-week #accelerator program is designed to prepare startups for more productive engagements with pharma, teaching them what they need to know. 🚀 🌏 PharmStars is a virtual #accelerator, open to digital health startups from around the world because healthcare #innovation has no bounds 🙌 and happens anywhere. Our Spring accelerator will focus on "Digital Innovations in #Oncology." Learn more and apply (deadline is February 1!) 👉 👉 👉  www.PharmStars.com for details and to apply

🔬 Lab-testing startups are gearing up for changes as the FDA rolls out new regulations. While the ruling may hike up development costs, there’s optimism among some entrepreneurs and investors. As highlighted by Brian Gormley, this shift could impact financing opportunities, narrowing the pool of venture capitalists willing to invest. Oriana Papin-Zoghbi, co-founder of PrognomiQ, acknowledges the challenges, particularly in the diagnostics market, where securing venture capital can be tough due to limited focus from investment firms. https://lnkd.in/etiEd4nB